Arno Therapeutics(OTC) ARNI

Market Cap$4.90K

Since IPO (2008)-100%

5 Year-98%

1 Year+9,900%

1 Month+9,900%

$0.00

+0%

+0.00Today

Arno Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-06-10

Arno Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+9,900%	USD 0.00	2026-01-30
1 month	+9,900%	USD 0.00	2026-01-30
3 month	+9,900%	USD 0.00	2026-01-30
Year to date	-50%	USD 0.00	2025-12-12
1 year	+9,900%	USD 0.00	2025-05-22
3 year	+0%	USD 0.00	2023-06-06
5 year	-98%	USD 0.01	2021-06-10
Since inception	-100%	USD 16.00	2008-06-11

Arno Therapeutics Financials at a Glance

Market Cap

$4.90K

Revenue (TTM)

$0.00

Net Income (TTM)

-$13.74M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.00

Volume

2,500

Open

$0.00

Price

$0.00

Volume

2,500

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.00

Volume

2,500

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

ARNI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arno Therapeutics

Arno Therapeutics, Inc. is a biopharmaceutical company based in Flemington, New Jersey, dedicated to developing innovative treatments for cancer and other serious health conditions. The company is advancing several promising compounds through clinical trials, focusing on addressing unmet medical needs in oncology.

Products and Services

Onapristone: A type 1 anti-progestin hormone blocker in Phase I/II trials for solid tumors
AR-12: An oral cancer therapy that has completed Phase I studies for various malignancies
AR-42: An innovative oral treatment targeting hematological malignancies and solid tumors in Phase I studies

Growth Outlook

Ongoing clinical trials for Onapristone may lead to significant advancements in cancer treatment
AR-12's successful Phase I completion opens pathways for further development and potential market entry
Collaborations with academic institutions enhance research capabilities and innovation potential

Financial Highlights

Recent quarterly net income reported at -$3.85 million, reflecting ongoing R&D investments
Cash and cash equivalents increased to $2.12 million, indicating improved liquidity
Trailing twelve months (TTM) revenue remains at $0, emphasizing the focus on development over immediate sales

Arno Therapeutics, Inc. is positioned in the biotechnology sector, focusing on the development of therapies that address critical health challenges. The company's pipeline includes several compounds that are currently in various stages of clinical trials, showcasing its commitment to innovation in cancer treatment. The ongoing research and development efforts, coupled with strategic partnerships, provide a solid foundation for future growth. Financially, while the company has not yet generated revenue, the increase in cash reserves indicates a focus on sustaining operations and advancing its clinical programs. Investors may find the company's potential for growth in the oncology market appealing, especially as it continues to progress through clinical trials and explore new therapeutic avenues.

AI Generated • Jul 2, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Flemington, NJ 08822, US

ARNI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

250.44%

Return on Capital

N/A

Return on Assets

-3193.55%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.90K

Shares Outstanding

49.35M

Volume

2.50K

Avg. Volume

56.452

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$11.06M

EBITDA

-$11.50M

Operating Cash Flow

-$7.62M

Capital Expenditure

$0.00

Free Cash Flow

-$7.62M

Cash & ST Invst.

$2.12M

Total Debt

$5.09K

Arno Therapeutics Performance Analysis

Arno Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2015-12-31	N/A
Q1	2016-03-31	N/A
Q2	2016-06-30	N/A
Q3	2016-09-30	N/A

Arno Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2015-12-31	-500.6%
Q1	2016-03-31	52.0%
Q2	2016-06-30	46.3%
Q3	2016-09-30	-66.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q3 2016YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.90K

N/A

Market Cap/Employee

$1.23K

N/A

Employees

N/A

Net Income

-$3.85M

-466.3%

EBITDA

-$3.85M

-33.9%

Quarterly Fundamentals

Name

Q3 2016YOY CHG

Total Cash

$2.12M

+1623.1%

Total Debt

$5.09K

-42.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$782.00

-84.6%

Short Term Debt

$4.31K

+16.0%

Return on Assets

-31.94%

N/A

Return on Invested Capital

3.47%

N/A

Free Cash Flow

-$1.14M

+49.2%

Operating Cash Flow

-$1.14M

+49.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IVBTInnovation1 Biotech Inc.

IVBTInnovation1 Biotech Inc.$0.00+0.00%

PANCPanacos Pharmaceuticals, Inc.

PANCPanacos Pharmaceuticals, Inc.$0.00+0.00%

BXRXQBaudax Bio, Inc.

BXRXQBaudax Bio, Inc.$0.00+0.00%

BTTXBetter Therapeutics, Inc.

BTTXBetter Therapeutics, Inc.$0.00+0.00%

KLDOKaleido Biosciences, Inc.

KLDOKaleido Biosciences, Inc.$0.00+0.00%

TNGNQTengion, Inc.

TNGNQTengion, Inc.$0.00+0.00%

CALACalithera Biosciences, Inc.

CALACalithera Biosciences, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOFISoFi Technologies

SOFISoFi Technologies$15.25-0.09%

INTCIntel

INTCIntel$81.88-0.05%

NVDANvidia

NVDANvidia$190.01-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$57.75-0.06%

FFord Motor Company

FFord Motor Company$15.28+0.02%

NOKNokia

NOKNokia$8.41-0.06%

JBLUJetBlue Airways

JBLUJetBlue Airways$5.72-0.05%

Questions About ARNI

What is the current price of Arno Therapeutics?

Arno Therapeutics is trading at $0.00 per share.

What is the 52-week range for Arno Therapeutics?

Over the past 52 weeks, Arno Therapeutics has traded between $0.00 and $0.00.

How much debt does Arno Therapeutics have?

Arno Therapeutics total debt is unavailable.

How much cash does Arno Therapeutics have on hand?

Arno Therapeutics does not have cash on hand data available.

What is Arno Therapeutics’s dividend yield?

Arno Therapeutics does not currently have a dividend yield.

Arno Therapeutics(OTC) ARNI

Arno Therapeutics Financials at a Glance

ARNI News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Arno Therapeutics

ARNI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Arno Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ARNI

What is the current price of Arno Therapeutics?

What is the 52-week range for Arno Therapeutics?

How much debt does Arno Therapeutics have?

How much cash does Arno Therapeutics have on hand?

What is Arno Therapeutics’s dividend yield?

Premium Investing Services